Access to one of the most clinically consequential drug classes in a generation remains deeply uneven across American states — and the gap between clinical need and actual prescribing may be widest among the populations who stand to benefit most. This real-world analysis exposes structural fault lines in how GLP-1 receptor agonists reach patients with obesity and type 2 diabetes, raising questions that go well beyond individual treatment decisions.
Drawing on pharmacy claims from the Komodo Healthcare Map covering approximately 330 million covered lives during calendar year 2023, investigators mapped GLP-1 RA utilization by state for both diabetes and obesity indications. They cross-referenced utilization rates against CDC Behavioral Risk Factor Surveillance System disease prevalence data for the same period and layered in Medicaid formulary classifications — categorizing each state's coverage stance as unrestricted, restricted, or absent for each indication. A particularly striking pattern emerged: GLP-1 RA prescribing for diabetes tracked closely with state-level diabetes prevalence among commercially insured patients, but this correlation broke down in ways the excerpt suggests differ meaningfully by insurance type and obesity indication — details that the full paper elaborates.
The broader significance here is that GLP-1 RAs have moved well beyond glycemic control. Cardiovascular outcome trials like LEADER and SELECT have established mortality-relevant benefits for semaglutide and liraglutide, yet formulary gatekeeping — especially within Medicaid, which covers disproportionately lower-income and higher-disease-burden populations — appears to create systematic underutilization precisely where clinical yield could be greatest. This cross-sectional design cannot establish causality, and claims data inherently miss uninsured patients entirely. Still, for a drug class now supported by multiple large Phase III trials and FDA approvals across indications, utilization gaps driven by coverage policy rather than clinical appropriateness represent a meaningful public health concern. The finding is confirmatory of known access inequities but adds geographic granularity that prior research lacked.